文献速递心律失常

房颤消融后房颤负荷变化与健康相关生活质量的关联:CIRCA-DOSE随机临床试验亚组研究

Association of Atrial Fibrillation Burden With Health-Related Quality of Life After Atrial Fibrillation Ablation: Substudy of the Cryoballoon vs Contact-Force Atrial Fibrillation Ablation (CIRCA-DOSE) Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2021-01-01

该研究为CIRCA-DOSE随机临床试验的二次分析,纳入346例接受首次导管消融的症状性、主要为低负荷房颤患者,植入心脏监测器评估消融前及术后12个月房颤负荷,并采用AFEQT评分评估生活质量。结果显示,消融后房颤负荷中位数从2.0%降至0%,每日房颤负荷绝对减少15.8分钟或相对减少0.63%对应AFEQT评分改善1分。结论提示低负荷阵发性房颤患者消融后房颤负荷降低可能与生活质量有临床意义的改善相关。

要点

  • 消融后房颤负荷中位数从2.0%降至0%,AFEQT评分改善与负荷降低相关。
  • 每日房颤负荷绝对减少15.8分钟对应AFEQT评分改善1分。
  • 相对房颤负荷减少0.63%对应AFEQT评分改善1分。

核心结论

  • 在主要为低负荷阵发性房颤患者中,消融后房颤负荷降低可能与生活质量有临床意义的改善相关。

研究设计与样本

  • 本研究为前瞻性、平行组、多中心、单盲随机临床试验(CIRCA-DOSE)的二次分析,在8个加拿大中心开展。
  • 2014年9月至2017年7月纳入346例年龄大于18岁、症状性、主要为低负荷、抗心律失常药物难治性房颤并转诊首次导管消融的患者。
  • 所有患者在消融前至少30天植入心脏监测器,随访至2018年12月;数据分析时间为2020年4月至2021年6月。
  • 患者按1:1:1随机分配至接触压力引导射频消融、4分钟冷冻球囊消融或2分钟冷冻球囊消融。

主要发现

  • 346例患者中231例(66.7%)为男性,中位年龄60(52-66)岁;328例(94.8%)为阵发性房颤。
  • 消融前房颤负荷中位数为2.0%(0.1-11.9),消融后12个月降至0%。
  • 消融后12个月,每日房颤负荷绝对减少15.8分钟(95% CI, 7.2-24.4; P < .001)对应AFEQT评分改善1分。
  • 相对房颤负荷较基线减少0.63%(95% CI, 0.30-0.95; P < .001)对应AFEQT评分改善1分。

临床怎么用

  • 对于主要为低负荷阵发性房颤患者,导管消融后房颤负荷降低可作为生活质量改善的参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with atrial fibrillation (AF) have impaired health-related quality of life primarily owing to symptoms related to AF episodes; however, quality of life can be influenced by AF therapies, AF complications, the frequency of follow-up visits and hospitalizations, illness perceptions, and patient factors, such as anxiety or depression. OBJECTIVE: To determine the association between change in AF burden and quality of life in the year following ablation. DESIGN, SETTING, AND PARTICIPANTS: The current study is a secondary analysis of a prospective, parallel-group, multicenter, single-masked randomized clinical trial (Cryoballoon vs Irrigated Radiofrequency Catheter Ablation: Double Short vs Standard Exposure Duration [CIRCA-DOSE] study), which took place at 8 Canadian centers. Between September 2014 and July 2017, 346 patients older than 18 years with symptomatic, primarily low-burden AF refractory to antiarrhythmic therapy referred for first catheter ablation were enrolled. All patients received an implantable cardiac monitor at least 30 days before ablation and were followed up with up to December 2018. Data were analyzed from April 2020 to June 2021. INTERVENTIONS: Patients were randomized 1:1:1 to contact force-guided radiofrequency ablation, 4-minute cryoballoon ablation, or 2-minute cryoballoon ablation. The exposure in the present analysis is the absolute difference in AF burden prior to ablation and 12 months following ablation, as evaluated by the Atrial Fibrillation Effect on Quality of Life (AFEQT) Score. MAIN OUTCOMES AND MEASURES: Absolute difference in quality of life from baseline to 12 months postablation. RESULTS: Of 346 included patients, 231 (66.7%) were male, and the median (interquartile range) age was 60 (52-66) years. A total of 328 patients (94.8%) had paroxysmal AF. The median (interquartile range) preablation AF burden was 2.0% (0.1-11.9), and the AF burden decreased to 0% at 12 months postablation. At 12 months, a 1-point improvement in AFEQT score was observed for every absolute reduction in daily AF burden of 15.8 minutes (95% CI, 7.2-24.4; P < .001), or every 0.63% (95% CI, 0.30-0.95; P < .001) reduction in relative AF burden from baseline. CONCLUSIONS AND RELEVANCE: In patients with primarily low-burden paroxysmal AF, the reduction in AF burden following ablation may be associated with a clinically meaningful improvement in quality of life. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01913522.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Samuel M, Khairy P, Champagne J, et al. Association of Atrial Fibrillation Burden With Health-Related Quality of Life After Atrial Fibrillation Ablation: Substudy of the Cryoballoon vs Contact-Force Atrial Fibrillation Ablation (CIRCA-DOSE) Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 34406350. doi:10.1001/jamacardio.2021.3063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。